Adjuvant Endocrine Therapy
Showing 1 - 25 of >10,000
Breast Tumors, Breast Cancer Trial (PACHA Program)
Not yet recruiting
- Breast Neoplasms
- Breast Cancer
- PACHA Program
- (no location specified)
Jun 6, 2023
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)
Not yet recruiting
- Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Giredestrant
- +6 more
- (no location specified)
Sep 26, 2023
Breast Cancer, Early Breast Cancer Trial (Camizestrant, Tamoxifen, Anastrozole)
Not yet recruiting
- Breast Cancer, Early Breast Cancer
- Camizestrant
- +4 more
- (no location specified)
Mar 7, 2023
Breast Cancer, Adherence, Medication, Side Effect Trial in New Haven (BETA-Text text messaging intervention)
Active, not recruiting
- Breast Cancer
- +2 more
- BETA-Text text messaging intervention
-
New Haven, ConnecticutYale Cancer Center
Aug 10, 2022
Breast Cancer, Quality of Life, Self Efficacy Trial in Leuven (Co'moon (online website to support women with AET))
Recruiting
- Breast Cancer
- +2 more
- Co'moon (online website to support women with AET)
-
Leuven, Vlaams-Brabant, BelgiumUZ Leuven campus Gasthuisberg
May 18, 2022
Breast Cancer, Survivorship, Treatment Compliance Trial in United States (Culturally Aware Adjuvant Endocrine Therapy (AET)
Not yet recruiting
- Breast Cancer
- +4 more
- Culturally Aware Adjuvant Endocrine Therapy (AET) Non-Initiation Intervention
-
Boston, Massachusetts
- +3 more
Jul 25, 2022
Breast Cancer Trial in Limoges, Villejuif (Anti-aromatase inhibitor)
Not yet recruiting
- Breast Cancer
- Anti-aromatase inhibitor
-
Limoges, France
- +1 more
Jul 25, 2022
Breast Cancer Female Trial in Charlottesville, Richmond (tamoxifen, letrozole, anastrozole, or exemestane, Patient reported
Recruiting
- Breast Cancer Female
- tamoxifen, letrozole, anastrozole, or exemestane
- Patient reported outcomes
-
Charlottesville, Virginia
- +1 more
Mar 16, 2022
Breast Cancer, Treatment Adherence, Quality of Life Trial in Stockholm (Digitized support)
Recruiting
- Breast Cancer
- +3 more
- Digitized support
-
Stockholm, Sweden
- +2 more
May 10, 2022
Breast Cancer Trial in Beijing, Guangzhou (TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen, Placebo capsules, Letrozole,
Not yet recruiting
- Breast Cancer
- TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen
- Placebo capsules, Letrozole, Anastrozole, Tamoxifen
-
Beijing, Beijing, China
- +1 more
Mar 10, 2023
Breast Cancer Trial in Washington, Baltimore (Outcomes4Me, Semi-structured interview)
Recruiting
- Breast Cancer
- Outcomes4Me
- Semi-structured interview
-
Washington, District of Columbia
- +1 more
Jan 13, 2023
Breast Cancer Trial in Zhengzhou (Capecitabine+endocrine therapy, Placebo+endocrine therapy)
Recruiting
- Breast Cancer
- Capecitabine+endocrine therapy
- Placebo+endocrine therapy
-
Zhengzhou, Henan, ChinaHenan cancer hospital
Nov 19, 2022
Breast Cancer Trial (Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression)
Not yet recruiting
- Breast Cancer
- Ovarian Function Suppression + Aromatase Inhibitor
- Adjuvant Chemotherapy + Ovarian Function Suppression
- (no location specified)
May 19, 2023
Breast Cancer, Adherence, Medication Trial in Boston (STRIDE, Medication Monitoring Control)
Completed
- Breast Cancer
- Adherence, Medication
- STRIDE
- Medication Monitoring Control
-
Boston, MassachusettsMassachusetts General Hospital Cancer Center
Nov 7, 2022
HR+/HER2-breast Cancer Trial (Standard endocrine therapy plus Apatinib)
Not yet recruiting
- HR+/HER2-breast Cancer
- Standard endocrine therapy plus Apatinib
- (no location specified)
Jun 2, 2023
Self-management Intervention (SM-AET), General Health Education Trial in Durham (SM-AET, general health education)
Active, not recruiting
- Self-management Intervention (SM-AET)
- General Health Education
- SM-AET
- general health education
-
Durham, North CarolinaDuke University Medical Center
Jun 22, 2022
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer Trial in United States (Pertuzumab+TRASTUZUMAB,
Recruiting
- HER2-positive Breast Cancer
- +5 more
- Pertuzumab+TRASTUZUMAB
- ADJUVANT ENDOCRINE THERAPY
-
Stamford, Connecticut
- +21 more
Dec 12, 2022
Breast Cancer, Early Breast Cancer Trial (Camizestrant, Tamoxifen, Anastrozole)
Not yet recruiting
- Breast Cancer, Early Breast Cancer
- Camizestrant
- +5 more
- (no location specified)
Jul 11, 2023
Breast Cancer Trial in United States (Palbociclib, Aromatase Inhibitor)
Completed
- Breast Cancer
- Palbociclib
- Aromatase Inhibitor
-
San Francisco, California
- +9 more
Mar 18, 2022
Breast Cancer, Quality of Life Trial in Chapel Hill (Accelerated Partial Breast Irradiation (APBI), tamoxifen, anastrozole,
Recruiting
- Breast Cancer
- Quality of Life
- Accelerated Partial Breast Irradiation (APBI)
- tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene
-
Chapel Hill, North CarolinaUniversity of North Carolina
Jul 22, 2022
Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and
Recruiting
- Hormone Receptor Positive HER-2 Negative Breast Cancer
-
Tuebingen, GermanyDepartment of Women's Health
Jun 1, 2023
Early Stage Breast Cancer: Adherence and Clinical Outcome
Completed
- Breast Neoplasm
-
Trondheim, NorwaySt Olavs Hospital
Apr 30, 2021